ReviewJournal of cardiovascular translational research2017
Utilizing the Foreign Body Response to Grow Tissue Engineered Blood Vessels in Vivo.
Review in Journal of cardiovascular translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 62 citations in OpenAlex.
- Reinforced biotubes as readily available and regenerative vascular grafts.Nature communications · 2026Article
- Don't judge an implant by its cover: how the foreign body response and fibrotic capsule might be harnessed for good.npj biomedical innovations · 2026Review
- Engineering the Future of Stem Cells in Vascular Reconstruction: A Leap Towards Functional Endothelialized Tissue-Engineered Vascular Conduits.Stem cell reviews and reports · 2025Article
- Biological responses to biomaterials: a review.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025Review
- Utilization of a highly adaptable murine air pouch model for minimally invasive testing of the inflammatory potential of biomaterials.Frontiers in bioengineering and biotechnology · 2024Article
- Review
- Functionalization ofBioactive materials · 2023Article
- Current Strategies for Engineered Vascular Grafts and Vascularized Tissue Engineering.Polymers · 2023Review
- Progress in the application of patch materials in cardiovascular surgery.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- Vascular Grafts: Technology Success/Technology Failure.BME frontiers · 2023Review
- Clinical implications of inflammation in atheroma formation and novel therapies in cardiovascular diseases.Frontiers in cell and developmental biology · 2023Review
- Bioengineering Human Tissues and the Future of Vascular Replacement.Circulation research · 2022Review
- Mechanically reinforced biotubes for arterial replacement and arteriovenous grafting inspired by architectural engineering.Science advances · 2022Article
- Review
- Macrophages and vimentin in tissues adjacent to megaprostheses and mesh in reconstructive surgeries.Communicative & integrative biology · 2022Article
- Emerging Materials and Technologies with Applications in Flexible Neural Implants: A Comprehensive Review of Current Issues with Neural Devices.Advanced materials (Deerfield Beach, Fla.) · 2021Review
- Biomimetic Elastin Fiber Patch in Rat Aorta Angioplasty.ACS omega · 2021Article
- Review
- Arteriovenous access in hemodialysis: A multidisciplinary perspective for future solutions.The International journal of artificial organs · 2021Review
- Tissue Engineered Vascular Graft Recipient Interleukin 10 Status Is Critical for Preventing Thrombosis.Advanced healthcare materials · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well known that the number of patients requiring a vascular grafts for use as vessel replacement in cardiovascular diseases, or as vascular access site for hemodialysis is ever increasing. The development of tissue engineered blood vessels (TEBV's) is a promising method to meet this increasing demand vascular grafts, without having to rely on poorly performing synthetic options such as polytetrafluoroethylene (PTFE) or Dacron. The generation of in vivo TEBV's involves utilizing the host reaction to an implanted biomaterial for the generation of completely autologous tissues. Essentially this approach to the development of TEBV's makes use of the foreign body response to biomaterials for the construction of the entire vascular replacement tissue within the patient's own body. In this review we will discuss the method of developing in vivo TEBV's, and debate the approaches of several research groups that have implemented this method.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.